Xeomin (botulinum neurotoxin type A) for treating lower or upper limb spasticity in people 2 to 17 years [TSID12297] None selected Not selected 20 November 2025 Gilteritinib + daunorubicin + ...
Final guidance published today (Thursday 4 December 2025) conditionally recommends seven digital technologies that can support cardiac rehabilitation for adults with cardiovascular disease in the NHS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback